share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K：重大事件
美股SEC公告 ·  09/25 16:15

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. has reported significant changes in its corporate structure and accounting practices. On September 20, 2024, the company's independent registered public accounting firm, EisnerAmper LLP, resigned. The audit reports for the fiscal years ending December 31, 2023, and December 31, 2022, by EisnerAmper did not contain any adverse opinions but included a paragraph about the company's ability to continue as a going concern. There were no disagreements on accounting principles or practices during the two fiscal years. Following the resignation, Virpax Pharmaceuticals appointed a new auditor, Bush & Associated CPA LLC, on September 24, 2024, as approved by the Audit Committee and ratified by the Board of Directors. Additionally, on the same day as the auditor's resignation, Eric Floyd, Chairman of the Board, resigned from his position and all committee roles due to disagreements with the Board's policies and practices, including salary reductions and the elimination of directors' and officers' insurance. These changes come at a critical time for the company and are disclosed in the company's recent SEC filings.
Virpax Pharmaceuticals, Inc. has reported significant changes in its corporate structure and accounting practices. On September 20, 2024, the company's independent registered public accounting firm, EisnerAmper LLP, resigned. The audit reports for the fiscal years ending December 31, 2023, and December 31, 2022, by EisnerAmper did not contain any adverse opinions but included a paragraph about the company's ability to continue as a going concern. There were no disagreements on accounting principles or practices during the two fiscal years. Following the resignation, Virpax Pharmaceuticals appointed a new auditor, Bush & Associated CPA LLC, on September 24, 2024, as approved by the Audit Committee and ratified by the Board of Directors. Additionally, on the same day as the auditor's resignation, Eric Floyd, Chairman of the Board, resigned from his position and all committee roles due to disagreements with the Board's policies and practices, including salary reductions and the elimination of directors' and officers' insurance. These changes come at a critical time for the company and are disclosed in the company's recent SEC filings.
Virpax制药公司报告了公司架构和会计实践方面的重大变化。2024年9月20日，公司独立的注册会计师事务所EisnerAmper LLP辞职。EisnerAmper在截至2023年12月31日和2022年12月31日的财政年度的审计报告中没有包含任何不利意见，但包括了一段关于公司继续作为持续经营的能力的内容。在这两个财政年度内，关于会计原则或实践的争议不存在。在辞职后，Virpax制药公司于2024年9月24日任命了新的审计师Bush & Associated CPA LLC，经审计委员会批准并董事会批准。此外，就在审计师辞职的同一天，董事会主席Eric Floyd因与董事会的政策和实践存在分歧，包括薪酬减少以及取消董事和高管保险等，而辞去了他的职务和所有委员会角色。这些变化发生在公司关键时期，并已在公司最近的SEC申报文件中披露。
Virpax制药公司报告了公司架构和会计实践方面的重大变化。2024年9月20日，公司独立的注册会计师事务所EisnerAmper LLP辞职。EisnerAmper在截至2023年12月31日和2022年12月31日的财政年度的审计报告中没有包含任何不利意见，但包括了一段关于公司继续作为持续经营的能力的内容。在这两个财政年度内，关于会计原则或实践的争议不存在。在辞职后，Virpax制药公司于2024年9月24日任命了新的审计师Bush & Associated CPA LLC，经审计委员会批准并董事会批准。此外，就在审计师辞职的同一天，董事会主席Eric Floyd因与董事会的政策和实践存在分歧，包括薪酬减少以及取消董事和高管保险等，而辞去了他的职务和所有委员会角色。这些变化发生在公司关键时期，并已在公司最近的SEC申报文件中披露。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间